Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 482-400-9 | CAS number: 138776-88-2
Endpoint summary
Administrative data
Description of key information
Key value for chemical safety assessment
Skin sensitisation
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed (sensitising)
- Additional information:
The Local Lymph Node Assay (LLNA) was conducted to assess the potential of6,6'-[[3,3',5,5'-tetrakis(1,1-dimethylethyl)-[1,1'- biphenyl]-2,2'-diyl] bis(oxy)]bis-dibenzo[d,f][1,3,2]-dioxaphosphepinto cause contact sensitization by measuring lymphocyte proliferative responses from auricular lymph nodes following topical application of the test material to the mouse ear.
Screening Study: Three daily topical applications of 1%, 5%, 10%, or 25% of the test material were given to one animal at each dose level. Erythema was absent and body weights were unaffected in all dose groups. Results from this study were used to determine the dosing concentrations for the test material in the LLNA. LLNA: Six female mice/group received 1%, 5%, or 25% of the test material or vehicle (dimethylformamide; (DMF)) or 30% α-hexylcinnamaldehyde (HCA; positive control) on days 1-3. On day 6, uptake of 3Hthymidine into the auricular lymph nodes draining the site of chemical application was measured five hours post administration. Proper conduct of the LLNA was confirmed via a positive response using 30% α- hexylcinnamaldehyde (HCA), a moderate contact sensitizer, which elicited proliferation that was 11.4 times greater than vehicle-treated mice. Erythema was absent and body weights were unaffected in all dose groups. Mice treated with 1%, 5% and 25% of the test material elicited proliferative responses with stimulation indices (SI) that were respectively 1.4, 1.0, and 3.1 in comparison to vehicle-treated mice. The concentration that would cause a 3-fold increase in proliferation (EC3) was calculated to be 24.1% which is consistent with weak dermal sensitization potential as described by an expert ECETOC panel (Technical Report No. 87, 2003).
Respiratory sensitisation
Endpoint conclusion
- Endpoint conclusion:
- no study available
Justification for classification or non-classification
6,6'-[[3,3',5,5'-tetrakis(1,1-dimethylethyl)-[1,1'- biphenyl]-2,2'-diyl] bis(oxy)]bis-dibenzo[d,f][1,3,2]-dioxaphosphepin has an estimated EC3 of 24.1%, which is consistent with weak dermal sensitization potential, and is classified as a Skin sensitiser 1B.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
